Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13

Journal of Medicinal Chemistry

Volumn 52, Issue 11, 2009, Pages 3523-3538

  Monovich, Lauren G ^a   Tommasi, Ruben A ^a   Fujimoto, Roger A ^a   Blancuzzi, Vincent ^a   Clark, Kirk ^a   Cornell, Wendy D ^a   Doti, Robert ^a   Doughty, John ^a   Fang, James ^a   Farley, David ^a   Fitt, John ^a   Ganu, Vishwas ^a   Goldberg, Ronald ^a   Goldstein, Robert ^a   Lavoie, Stacey ^a   Kulathila, Raviraj ^a   Macchia, William ^a   Parker, David T ^a   Melton, Richard ^a   O'Byrne, Elizabeth ^a   Pastor, Gary ^a   Pellas, Theodore ^a   Quadros, Elizabeth ^a   Reel, Noela ^a   Roland, Dennis M ^a   Sakane, Yumi ^a   Singh, Hem ^a   Skiles, Jerry ^a   Somers, Joseph ^a   Toscano, Karen ^a   Wigg, Andrew ^a   Zhou, Siyuan ^a   Zhu, Lijuan ^a   Shieh, Wen Chung ^a   Xue, Song ^a   McQuire, Leslie W ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(BENZOFURAN 2 SULFONYLAMINO)CARBOXYMETHYL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; 4 [CARBOXY (5 PHENYLTHIOPHENE 2 SULFONYLAMINO)METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY (5 PYRIDIN 2 YLTHIOPHENE 2 SULFONYLAMINO)METHYL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 [CARBOXY (5 PYRIDIN 4 YLTHIOPHENE 2 SULFONYLAMINO)METHYL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 [CARBOXY [5 (3 ETHOXYPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 [CARBOXY [5 (4 N,N DIMETHYLAMINOPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 [CARBOXY [5 (4' ETHOXYPHENY)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (4' ETHOXYPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (4' ETHOXYPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID METHYL ESTER; 4 [CARBOXY [5 (4' HYDROXYPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (4' ISOPROPOXYPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (4' METHOXYPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (4' METHYLPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (4' N PROPOXYPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (4' PIPERIDIN 1 YLPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (4' PIPERIDIN 1 YLPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 [CARBOXY [5 (4' TRIFLUOROMETHOXYPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (4' TRIFLUOROMETHYLPHENYL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; 4 [CARBOXY [5 (6 METHOXYPYRIDIN 3 YL)THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; 4 [CARBOXY [5 [4' (2 METHOXYETHOXY)PHENYL]THIOPHENE 2 SULFONYLAMINO]METHYL]PIPERIDINE 1 CARBOXYLIC ACID ISOPROPYL ESTER; CARBOXYLIC ACID DERIVATIVE; CIPEMASTAT; COLLAGENASE 3; COLLAGENASE 3 INHIBITOR; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OSTEOARTHRITIS; PROTEIN SECRETION; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CARTILAGE; CATTLE; COLLAGEN TYPE II; CRYSTALLOGRAPHY, X-RAY; INHIBITORY CONCENTRATION 50; MATRIX METALLOPROTEINASE 13; PIPERIDINES; PROTEASE INHIBITORS; PROTEOGLYCANS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 66749184678     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801394m     Document Type: Article

References (63)

1. Cawston, T. E.; Wilson, A. J. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract. Res., Clin. Rheumatol. 2006, 20 (5), 983-1002. (Pubitemid 44356460)
2. Huxley-Jones, J.; Foord, S. M.; Barnes, M. R. Drug discovery in the extracellular matrix. Drug Discovery Today 2008, 13 (15/16), 685-694.
3. Rowan, A. D.; Litherland, G. J.; Hui, M.; Milner, J. M. Metalloproteases as potential therapeutic targets in arthritis treatment. Expert Opin. Ther. Targets 2008, 12 (1), 1-18.
4. Hu, J.; Van den Steen, P. E.; Sang, Q-X., A.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discovery 2007, 6 (6), 480-498. (Pubitemid 47064570)
5. Roach, H. I. Potential directions for drug development for osteoarthritis. Expert Opin. Drug Discovery 2008, 3 (5), 475-486.
6. Billinghurst, R. C.; Dahlberg, L.; Ionescu, M.; Reiner, A.; Bourne, R.; Rorabeck, C.; Mitchell, P.; Hambor, J.; Diekmann, O.; Tschesche, H.; Chen, J.; Van Wart, H.; Poole, A. R. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 1997, 99 (7), 1534-1545. (Pubitemid 27163804)
7. Takaishi, H.; Kimura, T.; Dalal, S.; Okada, Y.; D'Armiento, J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr. Pharma. Biotechnology 2008, 9 (1), 47-54.
8. Fibrillar collagen, an important component of cartilage, is cleaved most effectively by three collagenases, MMP-1 (collagenase-1), MMP-8 (collagenase-2), and MMP-13 (collagenase-3), making it susceptible to further degradation by the other MMPs.
9. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a nonpeptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 1997, 40, 2525-2532. (Pubitemid 27347016)
10. O'Byrne, E.; Blancuzzi, V.; Singh, H.; McPherson, L.; Parker, D.; Roberts, E. D. Chondroprotective activity of a matrix metalloprotease inhibitor, CGS 27023A, in animal models of osteoarthritis. In Advances in Osteoarthritis; Tanaka, S., Hamanishi, C., Eds.; Springer-Verlag: Tokyo, 1999, 163173.
11. Walker, K. Activity of a selective inhibitor of collagenase-3 in models of arthritis. First Annual International Conference on Orthopaedic Biomaterials, San Diego, CA, December 11-12, 1997. Campbell, J. A. Discovery of RS-130830, a potent and selective MMP inhibitor for osteoarthritis. Book of Abstracts, 216th ACS National Meeting; American Chemical Society: Washington, DC, 1998; MEDI-004.
12. Chau, T.; Jolly, G.; Plym, J. M.; McHugh, M.; Bortolon, E.; Wakefield, J. Inhibition of articular cartilage degradation in dog and guinea pig models of osteoarthritis by the stromelysin inhibitor BAY 12-9566. Arthritis Rheum. 1998, 41 (S9), S300.
13. Lorenz, H.-M. Ro-32-3555 Roche Holding. Curr. Opin. Anti-Inflammatory Immunol. Invest. Drugs 2000, 2 (1), 47-52.
14. Rhomberg, W. Marimastat. Curr. Opin. Oncol., Endocrinol., Metab. Invest. Drugs 1999, 1, 507-524.
15. Griffioen, A. AG-3340. IDrugs 2000, 3, 336-345.
16. Slawomir, W.-P.; Torri, J.; Johnson, M.; Steen, V.; Marshall, J.; Ness, E.; Dickson, R.; Sole, M.; Rosmussen, H.; Avanzato, C.; Hawkins, M. Phase I trials marimastat, a metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin. Oncol. 1998, 16, 2150-2156. (Pubitemid 28265052)
17. Steward, W. P. Marimastat (BB2516): current status of development, cancer. Chemother. Pharmacol. 1999, 43 (Suppl), S56-S60.
18. Levitt, N. C.; Eskens, F.; Propper, D. J. A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor. 34th Annual Meeting of the American Society of Clinical Oncology, 1998, 17, 213, 16. Clinical study, abstract.
19. Levitt, N. C.; Eskens, F. A. L. M.; O'Byrne, K. J.; Propper, D. J.; Denis, L. J.; Owen, S. J.; Choi, L.; Foekens, J. A.; Wilner, S.; Wood, J. M.; Nakajima, M.; Talbot, D. C.; Steward, W. P.; Harris, A. L.; Verweij, J. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, CGS 27023 (CGS27023A), in patients with advanced solid cancer. Clin. Cancer Res. 2001, 7 (7), 1912-1922. (Pubitemid 32994825)
20. Bayer and Agouron compete in MMP inhibitors field. Scrip, 1998, 2349, 20-21.
21. Hande, K.; Wilding, G.; Ripple, G. A phase I study of AG3340, a matrix metalloprotease inhibitor, in patients having advanced cancer. Ann. Oncol. 1998, 9 (Suppl. 2), 74 Clinical study, abstract.
22. Hande, K. R.; Collier, M.; Paradiso, L.; Stuart-Smith, J.; Dixon, M.; Clendeninn, N.; Yeun, G.; Alberti, D.; Binger, K.; Wilding, G. Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clin. Cancer Res. 2004, 10 (3), 909-915.
23. Collier, M. A.; Yuen, G. J.; Bansal, S. K. A phase I study of the matrix metalloproteinase inhibitor AG3340 given in single doses to healthy volunteers; 88th Annual Meeting of the American Association for Cancer Research, 1997, 221, abstract.
24. The uncertainty as to the cause of the side effects continues as discussed in (a) Fingleton, B. Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 2007, 13 (3), 333-346.
25. (b) Peterson, J. T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 2006, 69 (3), 677-687.
26. McGeehan, G. M.; Becherer, J. D.; Bast, R. C.; Boyer, C. M.; Champlon, B.; Connolly, K. M.; Conway, J. G.; Furdon, P.; Karp, S.; Kidao, S.; McElroy, A. B.; Nichols, J.; Pryzwansky, K. M.; Schoenen, F.; Sekut, L.; Truesdale, A.; Verghese, M.; Warner, J.; Ways, J. P. Regulation of tumour necrosis factor - a processing by a metalloproteinase Inhibitor. Nature 1994, 370, 558.
27. Peschon, J. J.; Slack, J. L.; Reddy, P.; Stocking, K. L.; Sunnarborg, S. W.; Lee, D. C.; Russell, W. E.; Caster, B. J.; Johnson, R. E.; Fitzner, J. N.; Boyce, R. W.; Nelson, N.; Kozlosky, C. J.; Wolfon, M. F.; Rauch, C. T.; Ceretti, D. P.; Paxton, R. J.; March, C. J.; Black, R. A. An essential role for ectodomain shedding in mammalian development. Science 1998, 282, 1281-1284. (Pubitemid 28524483)
28. Gallea-Robache, S.; Morand, V.; Millet, S.; Btuneau, J.-M.; Bhatnagar, N.; Chouaib, S.; Roman-Roman, S. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 1997, 9, 340-346. (Pubitemid 27248243)
29. Hooper, N. M.; Kariran, E. H.; Turner, A. J. Membrane protein secretases. Biochem. J. 1997, 321, 265-279. (Pubitemid 27056469)
30. Montana, J.; Baxter, A. The design of selective non-substrate-based matrix metalloproteinase inhibitors. Curr. Opin. Drug Discovery Dev. 2000, 3, 353-361.
31. Farrah Kheradmand, F.; Zena Werb, Z. Shedding light on sheddases: role in growth and development. BioEssays 2002, 24, 8-12.
32. (a) Huovila, A-P. J.; Turner, A. J.; Pelto-Huikko, M.; Kaerkkaeinen, I.; Ortiz, R. M. Shedding light on ADAM metalloproteinases. Trends Biochem. Sci. 2005, 30 (7), 413-422.
33. Inhibition of TACE can be expected to build-up the substrate proTNF-α on the cell surface. Subsequent cleavage of proTNF-α by TACE at concentrations below effective inhibitor concentrations could yield high bursts of the proinflammatory mediator TNFa product.
34. Bayer and Agouron compete in MMP (matrix metalloproteinase) inhibitor field. Scrip Daily, 1998, July 2.
35. Parker, M. H.; Lunney, E.; Ortwine, D.; Pavlovsky, G.; Humblet, C.; Brouillette, C. G. Analysis of the binding of Hydroxamic acid and Carboxylic acid Inhibitors to the Stromelysin-1 (matrix Metalloproteinase- 3) Catalytic Domain by Isothermal Titration Calorimetry. Biochemistry 1999,3813592-13601
36. Garmer, D. R; Gresh, N.; Roques, B.-P. Modeling of Inhibitor- Metalloenzyme Interactions and Selectivity Using Molecular Mechanics Grounded in Quantum Chemistry. Proteins: Struct., Funct., Genet. 1998, 31, 42-60. (Pubitemid 28180454)
37. Castelhano, A. L.; Billedeau, R.; Dewdney, N.; Donnelly, S.; Horne, S.; Kurz, L. J.; Liak, T. J.; Martin, R.; Uppington, R.; Yuan, Z.; Krantz, A. Novel Indolactam-Based Inhibitors of Matrix Metalloproteinases. Bio. Med. Chem. Lett 1995, 5, 1415-1420.
38. Donini, O. A. T.; Kollman, P. Calculation and prediction of binding free energies for the matrix metalloproteinases. J. Med. Chem. 2000, 43, 4180-4188.
39. Aureli, L.; Gioia, M.; Cerbara, I.; Monaco, S.; Francesco, G.; Marini, S.; Ascenzi, P.; Topai, A.; Coletta, M. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. Curr. Med. Chem. 2008, 15, 2192-2222.
40. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99, 2735-2776.
41. Rao, B. G. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Des. 2005, 11 (3), 295-322.
42. An outstanding demonstration of this possibility is shown in Andrianjara, C.; Ortwine, D. F.; Pavlovsky, A. G.; Roark, W. H. Matrix metalloproteinase inhibitors. Patent WO 02/064080 A2, 2002.
43. In our hands, MMP inhibitor 3 showed modest activity in the primary MMP-13 in vitro assay (IC50 595 nM and >10000 nM with BSA present) and no activity in the rat IA model at 30 mg/kg, po.
44. Carboxylic acids are known to be strongly bound to plasma proteins and lipophilicity increases the binding.
45. Ghuman, J.; Zunszain, P. A.; Petitpas, I.; Ananyo, A.; Bhattacharya, M. O.; Curry, S. Structural Basis of the Drug-Binding Specificity of Human Serum Albumin. J. Mol. Biol. 2005, 353, 38-52.
46. After the completion of this work, very similar compounds were reported by scientists at Procter & Gamble Pharmaceuticals. (a) Pikul, S.; Ohler, N. E.; Ciszewski, G.; Laufersweiler, M. C.; Almstead, N. G.; De, B.; Natchus, M. G.; Hsieh, L. C.; Janusz, M. J.; Peng, S. X.; Branch, T. M.; King, S. L.; Taiwo, Y. O.; Mieling, G. E. Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. J. Med. Chem. 2001, 44 (16), 2499-2502.
47. Lewis, N.; McKillop, A.; Taylor, R. J. K.; Watson, R. J. A Simple and Efficient Procedure for the Preparation of Chiral 2-Oxazolidinones from R-amino acids. Synth. Commun. 1995, 25 (4), 561-568.
48. Bellina, F.; Carpita, A.; Rossi, R. Palladium catalysts for the Suzuki cross-coupling reaction: an overview of recent advances. Synthesis 2004, 15, 2419-2440. (a) Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457-2483. (Pubitemid 39457598)
49. (b) Li, C.-J. Angew. Chem. 2003, 115, 5004-5006.
50. Klebe, J. F.; Finkbeiner, H.; White, D. M. Silylations with Bis(trimethylsilyl) acetamide, a highly reactive silyl donor. J. Am. Chem. Soc. 1966, 88 (14), 3390-3395.
51. Lovejoy, B.; Welsh, A. R.; Carr, S.; Luong, C.; Broka, C.; VanWart, H.; Browner, M. F. Crystal Structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol. 1999, 6, 217-221.
52. Kragh-Hansen, U.; Chuang, V. T. G.; Otagiri, M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 2002, 25 (6), 695-704.
53. Fletcher, K.; Tinwell, H.; Ashby, J. Mutagenicity of the human bladder carcinogen 4-aminobiphenyl to the bladder of MutaMouse transgenic mice. Mutat. Res. 1998, 400 (1,2), 245-250.
54. Yuta, K.; Jurs, P. C. Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines. J. Med. Chem. 1981, 24, 241-251.
55. Ashby, J.; Elliott, B. M.; Keen, W.; Riley, E. Studies in vivo to investigate the status of 4-N-pyrrolidinylazobenzene as a pure cancer initiating agent to the rat liver. Cancer Lett. 1985, 27 (1), 115-122 (Pubitemid 15015776)
56. Ashby, J.; Paton, D.; Lefevre, P. A. Cyclic amines as less mutagenic replacements for dimethylamino (-NMe2) substituents on aromatic organic compounds: implications for carcinogenicity and toxicity. Cancer Lett. 1983, 17 (3), 263-271 (Pubitemid 13194041)
57. Hughes, C.; Murphy, G.; Hardingham, T. E. Metalloproteinase digestion of cartilage proteoglycan. Biochem. J. 1991, 279, 733-739.
58. Fosang, A. J.; Neame, P. J.; Last, K.; Hardingham, T. E.; Murphy, G.; Hamilton, J. A. The interglobular domain of cartilage aggrecan is cleaved by pump, gelatinases and cathepasin B. J. Biol. Chem. 1992, 267, 19470-19474.
59. Nguyen, Q.; Murphy, G.; Roughly, P. J.; Mort, J. S. Degradation of proteoglycan aggregate by a cartilage metalloproteinase: evidence for the involvement of stromelysin in the generation of link protein heterogeneity in situ. Biochem. J. 1989, 259, 61-67. (Pubitemid 19100497)
60. Okada, Y.; Konomi, H.; Yada, T.; Kimata, K.; Nagase, H. Degradation of type IX collagen by matrix metalloproteinase 3 (stromelysin) from human rheumatoid synovial cells. FEBS Lett. 1989, 473-476. (Pubitemid 19067171)
61. Buttner, F. H.; Chubinskaya, S.; Margerie, D.; Huch, K.; Flechtenmacher, J.; Cole, A. A.; Kuettner, K. E.; Bartnik, E. Expression of membrane type 1 matrix metalloproteinase in human articular cartilage. Arthritis Rheum. 1997, 40, 704-709. (Pubitemid 27157575)
62. Nagasel, H.; Fields, C. G. Fields G.B. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). J. Biol. Chem. 1994, 269, 20952.
63. Pathak, N.; Hu, S.-I.; Koehn, J. A. The expression, refolding, and purification of the catalytic domain of human collagenase-3 (MMP-13). Protein Expression Purif. 1998, 14, 283-288. (Pubitemid 28504175)